Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Olink Bioscience's Proseek Multiplex Protein Biomarker Immunoassays


Olink Bioscience this week launched its Proseek Multiplex multiplexed protein biomarker immunoassays. According to the Uppsala, Sweden-based firm, Proseek Multiplex enables users to quantify 92 proteins in a 1 microliter sample "without compromising data quality or performance."

The new offering is based on Olink's proximity extension assay platform. PEA uses pairs of antibodies equipped with DNA reporter molecules, which, upon target binding, give rise to new DNA amplicons that barcode their respective antigens for downstream identification. The amplicons are subsequently quantified by real-time PCR.

CEO Simon Fredriksson said in a statement that Olink intends to introduce a portfolio of protein biomarker assays. First in this range is its Proseek Multiplex Oncology I 96x96 kit, which is capable of analyzing 96 samples against a panel of analytes such as growth factors, inflammatory markers, soluble receptors, and cancer antigens. Fredriksson said that Olink plans to launch additional Proseek 92-plex panels for cardiovascular disease, inflammation, and diabetes this year.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.